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ABSTRACT 
Drug listing recommendations from health technology assessment (HTA) agencies often fail to 
coincide with one another. We conducted a comparative analysis of listing recommendations in 
Australia (PBAC), the Netherlands (CVZ), Sweden (TLV) and the UK (NICE) over time, examined 
interagency agreement, and explored how process-related factors—including time delay between 
HTA evaluations, therapeutic indication and orphan drug status, measure of health economic value, 
and comparator—impacted decision-making in drug coverage. Agreement was poor to moderate 
across HTA agency listing recommendations, yet it increased as the delay between HTA agency 
appraisals decreased, when orphan drugs were assessed, and when low-value medicines 
(immunosuppressants, antineoplastics) were removed from the sample. International differences in 
drug listing recommendations seem to occur in part due to inconsistencies in how the supporting 
evidence informs assessment, but also to differences in how domestic priorities shape the value-based 
decision-making process. 
Comparative Analysis of Drug Listing Recommendations 
 
3 
 
INTRODUCTION 
Health technology assessment (HTA) is frequently used to inform value-based decision-making. 
Since it involves systematically evaluating health economic evidence, HTA is supported by a growing 
number of digital resources and regulatory initiatives that promote the sharing of clinical data. In the 
US, for instance, all applicable clinical trials must submit results to the publicly searchable registry 
clinicaltrials.gov,(1) making submitted data available for use by international appraisers. Regulators, 
including England’s National Institute for Health and Care Excellence (NICE), may also require 
manufacturers to submit all clinical data within the company’s possession anywhere in the world prior 
to drug review.(2) Evidence from recent comparative studies indicates that a similar set of clinical 
trials are in fact made available to drug appraisals,(3,4) which might lead one to anticipate significant 
overlap in value-based decision-making on drug coverage around the world. 
 
Contrary to this expectation, a growing body of literature has found that the HTA-based decisions on 
whether to recommend public reimbursement of new medicines rarely coincide with one another.(5,6) 
The literature has generally examined this issue from the perspective of the last available listing 
recommendation, and has suggested that international differences are accounted by social 
determinants, including preferences for treatment, disease severity and rarity (7,8) and local clinical 
practice;(4) as well as methodological factors, including HTA design and sufficiency of 
pharmacoeconomic evidence,(7,9) and use of comparative data.(4) As has been previously argued, 
however, HTA is a complex process that cannot be fully understood if the perspective concentrates 
exclusively on final listing decisions.(10) Rather, social and methodological factors may impact final 
listing decisions, but only to the extent that they influence complex HTA processes that occur over 
time. 
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These complex processes are reflected in HTA agency listing recommendations, which may evolve as 
time passes. Periodic reassessment of cost-effectiveness may be mandated,(11) but it may also result 
from an appeal against initial opinions on listing,(12,13) ad hoc reassessment initiated by the 
emergence of new health economic evidence,(14) or risk-sharing agreements.(2) In England, for 
instance, public guidance may be reviewed and re-issued if there is significant new evidence that is 
likely to change opinions on drug listing.(2) Australian listing recommendations can also be deferred 
for further review or appealed on ‘procedural’ or ‘merit-based’ grounds. Sponsors are also allowed an 
unlimited number of resubmissions should new information become available, and can request an 
independent review of negative recommendations.(15) Australian authorities in fact highlight that a 
decision not to recommend or change listing status “does not represent a final … view about the 
merits of the medicine”, but rather contributes to an “improved understanding of the listing 
process”.(16)  
 
Therefore, to better understand the causes of disagreement in HTA-based decision-making, we 
conducted a comparative analysis of drug listing recommendations emerging over time from 
Australia, England, the Netherlands, and Sweden. Within this framework, we examined interagency 
agreement in drug listing, and how social and methodological factors pertaining to the assessment 
process—including therapeutic indication and orphan drug status, time delay between HTA 
evaluations, health economic value, and comparator—influenced listing recommendations. This 
analysis found that international differences in drug listing recommendations exist in part due to 
inconsistencies in how the supporting evidence informs assessment, but also to differences in how 
domestic priorities shape the value-based decision-making process.
METHODOLOGY 
Inclusion Parameters 
This study examined HTA review processes and drug listing decisions from four HTA agencies in 
Australia (PBAC), England (NICE), the Netherlands (CVZ; ‘Zorginstituut Nederland’ since 2014), 
and Sweden (TLV) between 2009 – 2013. These were selected as leading examples of agencies that 
make similar use of HTA to inform value-based decision-making in drug coverage (Table 1). The 
five-year period Jan 2009 – Dec 2013 was chosen in order to pragmatically optimize the size of our 
sample while also capturing contemporary HTA practice.  
 
Data Extraction 
HTA Appraisal Documents 
A stepwise approach was used to identify all drugs that were appraised by the four HTA agencies. 
This process first identified all unique molecules that were assessed by NICE between 2009 – 2013 
(n=102). Of these, reviews for 67 drugs were publicly available as of July 2014 from the PBAC, of 
which 56 were also found to have been appraised by the CVZ. Of those 56 drugs, the TLV was found 
to have assessed 43 through July 2014. Since appraisals were publicly available for those 43 drugs 
from Australian, Dutch, Swedish, and UK HTA agencies, they were used as a common sampling 
frame in this study. Drug name, indications, listing recommendations, year of assessment, incremental 
cost-effectiveness ratios (ICERs), and review comparators were then extracted from all appraisal 
documents corresponding to each of the 43 drugs. If multiple HTA evaluations existed for drug-
indication pairs, data was extracted from both the first and last appraisal that had been published 
through June 2014. For example, Australia’s PBAC evaluated the clinical- and cost-effectiveness of 
sorafenib for renal cell carcinoma in 2006, 2008, 2012, and 2013—the evaluation conducted in 2006 
was taken as the ‘first’ appraisal, while the one published in 2013 was classified as the ‘last’ available 
appraisal. 
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Listing recommendations were classified into four categories: ‘List’ (L), ‘list with restrictions’ 
(LWR), ‘deferral’ (D) and ‘do not list’ (DNL). Base case analyses defined restrictions on listing 
decisions by the presence of any constraint on use in the approved indication that would limit the 
population eligible for reimbursement. For the TLV, positive approvals that were assigned a ‘Generell 
Subvention’ (general subsidy) were categorized as ‘L’, while those given a ‘Begränsad Subvention’ 
(limited subsidy) were classified as ‘LWR’. System-specific restrictions—e.g. physician prescription, 
reimbursement authority requirements—were not considered. 
 
Summary ICER measures were also extracted for each drug-indication pair. These consisted of 
discrete, one-sided directional, or a range of values. If agencies accepted more than one ICER for 
individual drug-indication pairs—e.g. to reflect treatment across patient subgroups—an inclusive 
ICER range was derived using the lowest and highest ICER values approved by the agency. 
Furthermore, if different ICERs were provided for different comparators, the ICER value 
corresponding with comparators used by other agencies was recorded to permit cross-agency 
comparison; otherwise, an ICER range was constructed to encompass all comparators that were used. 
ICERs were converted to U.S. dollar equivalents using historical currency conversion rates from 
OANDA that corresponded to the year of evaluation.(17) Nominal ICER values were also converted 
to constant 2013 U.S. dollars using price inflation indices from the World Bank.(18) To permit 
comparison, analyses were restricted to ICERs that were measured in terms of cost per QALY. 
 
Supplementary Sources 
Anatomical Therapeutic Chemical (ATC) classifications for therapeutic main groups of drug-
indication pairs were obtained from the WHO Collaborating Centre for Drug Statistics Methodology’s 
ATC/DDD Index 2014. Orphanet was also used to obtain EU drug ‘orphan’ status for the 
corresponding indication.(19)  
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Analysis 
Two analytical endpoints were included within the main analyses: an assessment of the distribution of 
listing recommendations across the four national HTA agencies, and inter-country agreement in 
listing decisions. Both endpoints were further stratified across potential drivers of international 
discrepancies in drug listing recommendations.  
 
Listing Recommendations and HTA Agency Associations 
HTA agency listing rates were calculated by dividing the number of drug-indication pairs given an ‘L’ 
or ‘LWR’ recommendation by the total number of drug-indication pairs evaluated in each country. 
Pearson’s χ2 test for independence and odds ratios were used to test for, and measure the strength of, 
association between listing recommendations and issuing HTA agency. Correspondence analysis was 
used to visually examine the association between first and last available listing recommendations and 
issuing HTA agency in low-dimensional space.(20)  
 
Agreement in the Overall and Stratified Sample 
Agreement in drug-indication pair listing recommendations from the four HTA agencies was 
measured using Cohen’s kappa coefficients. These were categorized into different levels of agreement 
using previously established thresholds.(21) Building on the available literature on factors that may 
explain levels of agreement in listing recommendations, these were stratified by: ATC groupings for 
treatment indications and orphan drug status; time delay (years) between assessments from NICE and 
the other HTA agencies, categorized as ≤3 years, ≤2 years, ≤1 year, 0 years; and agreement in ICER 
and selection of comparator. This allowed us to consider the impact of social factors (preferences for 
treatment, disease severity and rarity) and methodological factors (evidence or pricing developments, 
health technology assessment) on the process of HTA-based decision-making.  
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Listing Recommendations and Assessments of Value  
Finally, this analysis examined the association between final available listing recommendations and 
ICERs, a health economic measure of value. This analysis included all drug-indication pairs for which 
ICER estimates were given in terms of cost per QALY gained. The bound to one-sided directional 
ICER estimates and ICER range midpoints were used if discrete ICER values were not reported. Any 
drug-indication pair that was found to be dominated by its comparator was excluded. 
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RESULTS 
 
Table 1 summarizes the policy context related to health technology assessment and drug listing in 
Australia, the Netherlands, Sweden, and the UK. Though there is much overlap in the overall review 
process used by all four HTA agencies, there are differences in how health economic evidence is 
used, and in the factors that are considered during appraisal.  
 
In sum, all four countries provide public guidance for health technology evaluations, and most rely 
primarily on manufacturer-submitted health economic analyses. NICE reviews manufacturer-
submitted health economic evidence, as other agencies do, but it also works with Technology 
Assessment Groups (TAGs) to independently assess the value from treatment. NICE is also the only 
HTA agency to use explicit willingness-to-pay thresholds when determining whether to recommend 
treatment coverage through the National Health Service. Although the CVZ does not apply a “hard 
limit” to willingness-to-pay thresholds, it does operate within a suggested “bandwidth”. All countries 
nevertheless claim that they consider severity of disease, health needs, and availability of alternative 
treatment when issuing listing recommendations. As the Netherlands and UK show, orphan drug 
status may also be considered. Australia’s PBAC and the Dutch CVZ explicitly indicate that budget 
impact is considered when developing HTA-based listing recommendations, whereas Swedish and 
UK authorities do not. Implementation of Swedish and Australian listing recommendations is 
prescriptive under certain circumstances, while those from the Netherlands and the UK are left at the 
discretion of higher authorities. Differences in the design and priorities of HTA may reflect different 
policy and social objectives, and could therefore contribute to differences in drug listing 
recommendations. Comparative analyses of drug listing recommendations are now used to explore 
this issue. 
 
[INSERT TABLE 1] 
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Listing Recommendations and HTA Agency Associations 
Appraisals for a total of 231 drug-indication pairs were considered in this analysis across the four 
HTA agencies. NICE evaluated 72 drug-indication pairs for the 43 drugs that were included in our 
sample. Appraisals for 61 drug-indication pairs were available from PBAC documents, 52 from TLV 
documents and 46 from CVZ documents published through July 2014. The difference in number of 
drug-indication pairs evaluated across the four agencies may reflect differences in HTA dissemination 
strategies, duration of regulatory review, and market launch strategies.(22,23) Of the 72 drug-
indication pairs obtained from NICE, antineoplastic agents (39%) and immunosuppressants (28%) 
were the two largest therapeutic classes represented. See Supplementary Material (eFigure 1) for a 
full breakdown of these 72 drug-indication pairs by ATC groups. 
 
For the medicines that were included in our sample, the TLV was most likely to issue a positive final 
listing recommendation, with a final listing rate of 0.92 across all drug-indication pairs that it 
considered. This was followed by the CVZ (0.89), PBAC (0.84) and NICE (0.75). Even though it 
appraised the highest number of drug-indication pairs, NICE nevertheless issued a larger number of 
positive listing recommendations compared to the other HTA agencies (Figure 1). For both NICE and 
the PBAC, however, listing rates were lowest after the first available assessment, and subsequently 
increased after last available review (Figure 1). This finding was most dramatic for the PBAC, whose 
listing rate increased from 0.46 to 0.84 in its final evaluation of drug-indication pairs. NICE listing 
rates followed a similar, albeit less dramatic, increase (0.69 to 0.75). Increases in listing rates may 
reflect improvements in the perceived value from drug treatment—likely spurred on by new clinical 
or economic evidence supporting the submission—as well as mechanisms for drug review. For 
instance, of all four HTA agencies, the PBAC published multiple evaluations for the largest number 
of drug-indication pairs (n=36). This likely reflects the fact that the PBAC is the only agency of the 
four considered that may defer a listing recommendation pending cost negotiations or further 
investigations into clinical safety or efficacy.  
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[INSERT FIGURE 1] 
 
The null hypothesis of independence between HTA agency and listing recommendations was rejected 
for both the first and last available appraisals (First: χ2 = 74.94; p < 0.01; Last: χ2 = 54.66; p < 0.01). 
Local odds ratios were therefore used to measure the association between HTA agencies and initial 
and final available listing recommendations (Table 2). The TLV and CVZ were most likely to issue 
positive listing recommendations; negative listing recommendations from the PBAC frequently 
became positive with time; and NICE was, generally speaking, most restrictive in the positive listing 
recommendations that it issued. 
 
[INSERT TABLE 2] 
 
These results were consistent with correspondence analysis (eFigure 2). The principal dimension in 
correspondence analysis biplots for first and last available assessments appeared to consistently 
highlight opposition in listing recommendations. However, while this appeared to initially represent 
opposition between positive (L) and negative (DNL/D) outcomes, opposition appeared to better 
reflect a choice between listing with or without restrictions in last available assessments. In settings 
where listing recommendations can change over time, this may suggest that HTA agencies generally 
become more accommodative and transition from considering ‘whether or not to list’ to ‘whether or 
not to list with restrictions’.  
 
The association between HTA agency and listing rates however varied by drug indication. To draw 
inference, we limited our analysis to ATC subgroups with a sample size of at least 5 drug-indication 
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pairs (antithrombotics, antineoplastics, and immunosuppressants). For each HTA agency, 
immunosuppressants were associated with a final listing rate that exceeded that of the entire sample 
(Figure 2). Apart from the CVZ, a similar phenomenon was observed for antithrombotic agents. In 
contrast, antineoplastics had a lower listing rate than the overall institutional average for NICE, PBAC 
and the TLV; the CVZ’s listing rate for antineoplastics was above the agency’s average (Figure 2). 
Please see the appendix for more information on all remaining indications (eFigure 3). 
 
[INSERT FIGURE 2] 
 
Agreement in the Overall and Stratified Sample 
Consistent with previous findings, there was poor to fair agreement in listing recommendations across 
all agency to agency pairings (Table 3). NICE listing recommendations most often agreed with those 
from the PBAC, while the lowest level of agreement was observed between PBAC and TLV listing 
recommendations. The overall level of agreement in listing outcomes generally increased as the delay 
between agency assessments decreased and when orphan drugs were assessed. Inter-rater agreement 
was lower for antineoplastics and immunosuppressants than that observed for the entire sample 
(Table 3). Removing L01- (antineoplastics) and L04-indicated (immunosuppressants) drug products 
tended to increase the overall level of agreement between listing recommendations from NICE and 
the PBAC, TLV, and CVZ (eTable 1). Agreement in listing recommendations also generally 
decreased between first and last available assessment, and there was poor to fair agreement in listing 
recommendations across the other factors that were considered (Table 3). 
 
[INSERT TABLE 3] 
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Listing Recommendations and Assessments of Value  
Final NICE listing rates decreased as ICERs increased. The agency approved all drug-indication pairs 
with an ICER of less than US$45,000 per QALY gained (n = 27), and most of those (0.93) with 
ICERs ranging between US$45,001 – US$60,000 (n = 14). Lower listing rates were observed for the 
six drug-indication pairs with ICERs between US$60,001 – US$75,000 (0.67), and for the 24 drug-
indication pairs with an ICER above US$75,001 (0.25). Antineoplastics (L01) were 
disproportionately associated with higher ICER values, and in the set of drugs that received a negative 
listing recommendation from NICE (ure 3. I).  
 
[INSERT FIGURE 3] 
 
Although the PBAC, TLV and CVZ less frequently published ICER data, there appeared to be a 
similar, albeit generally weaker, relationship between drug listing recommendations and ICER 
observations where data existed (eFigure 4-6). In light of earlier findings, these data suggest that 
NICE and the PBAC are less likely than the TLV and CVZ to recommend funding of medicines that 
are deemed to provide low value, many of which are indicated for cancer.  
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DISCUSSION 
HTA-Based Practices in Drug Listing  
All drugs appraised by England’s NICE between 2009-2013, and also evaluated by the Australian 
PBAC, Dutch CVZ, and Swedish TLV through July 2014, were included in this study (n = 43). This 
drug sample corresponded to a total of 231 drug-indication pairs with drug listing recommendations 
across the four agencies, of which the largest share came from NICE (n = 72). Antineoplastics and 
immunosuppressants were the largest therapeutic indications represented, together accounting for 
67% of all drug-indication pairs considered by NICE.  
 
Drug listing rates varied across Australian, Dutch, Swedish, and English HTA authorities. The 
Swedish TLV was the most generous of the four HTA agencies, with 92% of evaluated drug-
indication pairs ultimately receiving a positive (restricted + unrestricted) listing recommendation. This 
was followed by the Dutch CVZ (89%), the Australian PBAC (84%), and England’s NICE, which 
eventually approved 75% of the drug-indication pairs that it considered.  
 
However, listing recommendations changed over time in some cases, which could point to differences 
in the ability of public agencies to take in new evidence, or their procedures for drug evaluation and 
cost negotiation. This was most dramatic for the Australian PBAC, where domestic authorities gave 
46% and 84% of drug-indication pairs a positive listing recommendation after first and last available 
review, respectively. A similar, yet less dramatic, trend was observed for England’s NICE. While 
negative recommendations are believed to reflect insufficiencies in the supporting evidence, 
restrictions on use may represent an attempt to increase the cost-effectiveness of treatments.(24) That 
the number of restricted drug listing recommendations increase over time in Australia and England 
may therefore indicate that both countries use the regulatory process to improve value-for-money in 
drug spending.  
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Generally speaking, these findings point to different regulatory approaches to inform value-based 
decision-making, limit budget impact, or optimize value-for-money in pharmaceutical spending by 
patients and payers. Let us take Australia as a case study: this analysis finds that Australia’s PBAC 
often issues a ‘do not list’ recommendation following initial review, but becomes more likely to grant 
a permissive recommendation over time (‘list with restriction’). The agency is responsible for issuing 
recommendations on whether to list medicines onto Australia’s Pharmaceutical Benefits Scheme 
(PBS), the first national pharmaceutical reimbursement program to explicitly consider ‘value-for-
money’ as a prerequisite for formulary listing.(25) The PBAC is known to have at times issued 
controversial decisions regarding listing status, even for indications such as cancer where treatment 
availability may be socially mandated, and the agency only recommends public listing of medicines 
that are priced at a premium over comparable drugs if the scientific data demonstrably shows 
clinically significant improvements in effectiveness or reductions in toxicity.(25) The PBAC may also 
limit the number of subsidized indications for a given drug, or may require “stepped therapy” or a 
“continuation rule” for subsidized use.(25) The mandate to ensure value-for-money in pharmaceutical 
spending may therefore be supported by a regulatory process that institutionalizes deferral of listing 
decisions and repeated review. 
 
From another perspective, an extensive review process that better informs value-based decision-
making or improves efficiency in pharmaceutical spending may nevertheless delay patient access. 
Recent evidence in fact suggests that Australians wait longer than most other OECD nations to access 
new medicines.(26) Future comparative studies should examine health outcomes as well as unit-level 
availability, pricing, and spending for new medicines in Australia, Sweden, the Netherlands, and the 
UK to explore the potential trade-offs from different approaches to pharmaceutical regulation and 
appraisal. 
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Convergence in Drug Listing Recommendations 
This analysis found poor to modest agreement in the listing recommendations that were issued by 
Australian, Dutch, Swedish, and English HTA agencies. The overall level of agreement was highest 
for listing recommendations from Australia and the UK, and lowest for those issued by Australian and 
Swedish HTA agencies. Agreement also tended to decrease between first and last available listing 
recommendations. Since it has focused on the latter, this finding may suggest that the available 
literature underestimates the level of agreement in drug listing recommendations from HTA agencies, 
particularly for the period soon after initial market entry. 
 
To also examine how the available evidence, social and institutional preferences, and processes for 
health economic assessment are associated with agreement in drug listing recommendations, this 
study stratified its sample by the delay occurring between health technology assessments, therapeutic 
indication and orphan status, and agreement in ICERs and health economic comparators.  
 
Increasing the delay between HTA evaluations was associated with a decrease in the level of 
agreement between listing recommendations from NICE and the PBAC and TLV. This finding may 
suggest that HTA agencies differ in how they incorporate new evidence, and that this can in turn 
impact agreement across their respective listing recommendations. Agreement also tended to increase 
when the sample was limited to orphan medications, particularly for listing recommendations from 
NICE and the TLV and CVZ. These findings may suggest that common health needs and preferences 
can have a converging effect on drug listing recommendations.  
 
Within our sample, the divergence observed across all international drug listing recommendations was 
driven by disagreement on listing recommendations for L01- (antineoplastics) and L04- 
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(immunosuppressants) indicated drug products. Considered alongside the finding that antineoplastics 
and immunosuppressants are also often associated with comparatively low levels of assessed health 
economic value, these findings may suggest that considerations of value-for-money strongly influence 
drug listing decisions—particularly in the UK and Australia—and that they are an important source of 
discrepancy in international listing recommendations. 
 
Health economic evaluations are an important component to technological assessments. To examine 
how these influence listing decisions across countries, we evaluated the association between drug 
listing recommendations and a health economic measure of value, the incremental cost effectiveness 
ratio (ICER). 40-60% of commonly evaluated drug-indication pairs that provided ICER estimates 
received similar ICER assessments across agency pairings, though the proportion of ICERs in 
agreement generally decreased between first and last available assessment. Methodological 
differences in how value is assessed may therefore partly account for drug listing discrepancies—
perhaps particularly in final listing recommendations—though the extent to which this is true varies 
by setting. This, however, reaffirms our earlier findings suggesting that methodological features of 
health economic assessments are not the only cause of international disagreement in whether to 
publicly reimburse medicines. Any influence on international agreement in listing recommendations 
from features of HTA appears to be compounded by differences in institutional priorities, insofar as 
how they shape the regulatory process and value-based decision-making. To gauge the 
appropriateness of differences in listing recommendations, additional work is therefore needed to 
examine how institutional priorities and practices reflect societal needs and preferences for treatment. 
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CONCLUSION 
Consensus in global HTA has become an important health policy objective, as it represents an 
opportunity to both reduce duplication of regulatory effort and improve transparent, value-based 
decision-making in drug coverage. To better understand the causes of disagreement in HTA-based 
recommendations on whether to include medicines on publicly reimbursable drug lists, this study 
conducted a comparative analysis of drug listing recommendations emerging over time from 
Australia, the Netherlands, Sweden, and the UK. Although final drug listing rates in these countries 
are generally high, they vary considerably across settings and tend to increase over time in Australia 
and the UK. Still, there is poor to moderate agreement in the drug listing recommendations from these 
four highly-developed health systems, though this is associated with the time delay between health 
technology assessment, orphan drug status, and with medicinal classes that are deemed to provide low 
value-for-money (immunosuppressants, antineoplastics). Poor to moderate agreement in listing 
decisions is also compounded by HTA-based value assessments that rarely coincide with one another. 
International differences in drug listing recommendations therefore seem in part due to early 
inconsistencies in how the supporting evidence informs appraisal, but also to differences in how 
domestic priorities shape the regulatory process and value-based decision-making. Moving forward, 
additional work is needed to examine how well drug review processes and outcomes reflect social 
values regarding the trade-off between publicly subsidized drug coverage and use of resources. 
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EXHIBITS 
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Table 1. Health Technology Assessment and value-based decision-making in drug coverage  
 
Overview of policies related to the implementation of health technology assessment and its use in value-based decision-making in drug 
coverage. 
Sources: Adapted from (14,15,27–38) 
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Figure 1. HTA agency listing recommendations, by first or last available assessment 
 
 
[FIGURE 1 - SEPARATE FILE] 
 
Listing recommendations across agencies, by first and last available appraisal for drug-indication pairs evaluated by NICE 
between 2009-2013. Number of drug-indication pairs falling within each recommendation category are provided within each 
bar. Positive listing rates (L + LWR) are provided to the right of each stacked bar. 
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Table 2. Measure of association between listing recommendations and HTA agencies, by first or last available assessment 
 
 
Local odds ratios to measure the strength of association between HTA agencies and first (Left) and last (Right) available 
listing recommendations. Since Australia is the only country of the four to defer the issuance of listing recommendations, 
deferrals are not considered. Definitions: L = List; LWR = List With Restrictions; DNL  = Do Not List.
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Figure 2. HTA agency listing recommendations, by ATC group 
 
 
[FIGURE 2 – SEPARATE FILE] 
 
Number of drug-indication pair recommendations issued for therapeutic groups with ≥5 drug-indication pairs 
(antithrombotics, antineoplastics, immunosuppressants), by first (F) and last (L) available appraisals across the four HTA 
agencies considered. Positive listing rates (L + LWR) are provided to the right of each stacked bar. 
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Table 3. Agreement across HTA agency listing recommendations, with sample stratifications 
 
 
Agreement across agency listing recommendations, standard error and sample size. Levels of agreement are measured with 
kappa (𝝹) scores across all agency– agency pairs (top), and in sample stratifications comparing NICE and other HTA 
agencies (bottom). Kappa thresholds are defined as per Landis & Koch (1977) (21) – poor agreement: 𝝹 ≤ 0.00, slight 
agreement: 𝝹 = 0.01–0.20, fair agreement: 𝝹 = 0.21–0.40, moderate agreement: 𝝹 = 0.41–0.60, substantial agreement: 𝝹 = 
0.61–0.80, near perfect agreement: 𝝹 = 0.81–1.00. Statistical testing: *p < 0.10, **p < 0.05, ***p < 0.01. 
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Figure 3. Incremental cost-effectiveness ratios for NICE drug-indication pairs, by ATC group and listing recommendation 
 
 
[FIGURE 3 – SEPARATE FILE] 
 
Final available incremental cost effectiveness ratios (ICER) for NICE drug-indication pairs, by ATC group (x-axis), listing 
recommendation, and sorted by ATC group average ICER (USD/QALY). Sample includes all drug-indications pairs for 
which ICERs were available. Where ATC group has >1 observation, 95%CI are provided around group average ICER. All 
values presented in constant 2013 USD. 
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eFigure 1. Drug-indication pairs evaluated by NICE between 2009-2013, by class of indication 
 
 
 
Description of the sample of NICE drug-indication pairs included in the analysis. Number of drug-indication pairs per ATC 
group. Definitions: A10 = Drugs used in diabetes; B01 = antithrombotic agents; B02 = antihemorhagics; C01 = cardiac 
therapy; H01 = pituitary and hyathalamic hormones and analogues; J05 = antivirals for systemic use; L01 = antineoplastic 
agents; L02 = endocrine therapy; L03 = immunostimulants; L04 = immunosuppressants; M05 = drugs for bone diseases; 
R03 = drugs for obstructive airways diseases; S01 = ophthalmologicals. 
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eFigure 2. Correspondence analysis biplots representing graphical association between HTA agencies and listing 
recommendations 
 
 
(Left) First set of listing recommendations for drug-indication pairs: A significant majority of the inertia (77.2%) is 
explained by dimension 1. (Right) Final set of listing recommendations for drug-indication pairs: A majority of the inertia 
(84.1%) is explained by dimension 1. ‘L’: List; ‘LWR’: List with restrictions; ‘D’: Deferral; ‘DNL’: Do not list. ‘PBAC’: 
Australia HTA agency; ‘CVZ’: Dutch HTA agency; ‘TLV’: Swedish HTA agency; ‘NICE’: UK HTA agency. 
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eFigure 3. HTA agency listing recommendations, by ATC group 
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eTable 1. Agreement across HTA agency listing recommendations, without immunosuppressants, antineoplastics, 
antithrombotic 
 
 
Agreement across agency listing recommendations, standard error, and sample size, after removing L01, L04, and B01 
indicated drug products. Levels of agreement measured by kappa (κ) scores, with categorical kappa thresholds defined per 
Landis & Koch (1977) as poor agreement: 𝝹 ≤ 0.00, slight agreement: 𝝹 = 0.01–0.20, fair agreement: 𝝹 = 0.21–0.40, 
moderate agreement: 𝝹 = 0.41–0.60, substantial agreement: 𝝹 = 0.61–0.80, near perfect agreement: 𝝹 = 0.81–1.00. Statistical 
testing: *p < 0.10, **p < 0.05, ***p < 0.01.
Comparative Analysis of Drug Listing Recommendations 
 
eFigure 4. Incremental cost-effectiveness ratios for PBAC drug-indication pairs, by ATC group and listing recommendation 
 
 
Final available incremental cost effectiveness ratios (ICER) for PBAC drug-indication pairs, by ATC group (x-axis), listing 
recommendation, and sorted by ATC group average ICER (USD/QALY). Sample includes all drug-indications pairs for 
which ICERs were available. Where ATC group has >1 observation, 95%CI are provided around group average ICER. All 
values presented in constant 2013 USD. Definitions: A10 = Drugs used in diabetes; B01 = antithrombotic agents; B02 = 
antihemorhagics; C01 = cardiac therapy; H01 = pituitary and hyathalamic hormones and analogues; J05 = antivirals for 
systemic use; L01 = antineoplastic agents; L02 = endocrine therapy; L03 = immunostimulants; L04 = immunosuppressants; 
M05 = drugs for bone diseases; R03 = drugs for obstructive airways diseases; S01 = ophthalmologicals. 
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eFigure 5. Incremental cost-effectiveness ratios for TLV drug-indication pairs, by ATC group and listing recommendation 
 
 
Final available incremental cost effectiveness ratios (ICER) for TLV drug-indication pairs, by ATC group (x-axis), listing 
recommendation, and sorted by ATC group average ICER (USD/QALY). Sample includes all drug-indications pairs for 
which ICERs were available. Where ATC group has >1 observation, 95%CI are provided around group average ICER. All 
values presented in constant 2013 USD. Definitions: A10 = Drugs used in diabetes; B01 = antithrombotic agents; B02 = 
antihemorhagics; C01 = cardiac therapy; H01 = pituitary and hyathalamic hormones and analogues; J05 = antivirals for 
systemic use; L01 = antineoplastic agents; L02 = endocrine therapy; L03 = immunostimulants; L04 = immunosuppressants; 
M05 = drugs for bone diseases; R03 = drugs for obstructive airways diseases; S01 = ophthalmologicals. 
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eFigure 6. Incremental cost-effectiveness ratios for CVZ drug-indication pairs, by ATC group and listing recommendation 
 
 
Final available incremental cost effectiveness ratios (ICER) for CVZ drug-indication pairs, by ATC group (x-axis), listing 
recommendation, and sorted by ATC group average ICER (USD/QALY). Sample includes all drug-indications pairs for 
which ICERs were available. Where ATC group has >1 observation, 95%CI are provided around group average ICER. All 
values presented in constant 2013 USD. Definitions: A10 = Drugs used in diabetes; B01 = antithrombotic agents; B02 = 
antihemorhagics; C01 = cardiac therapy; H01 = pituitary and hyathalamic hormones and analogues; J05 = antivirals for 
systemic use; L01 = antineoplastic agents; L02 = endocrine therapy; L03 = immunostimulants; L04 = immunosuppressants; 
M05 = drugs for bone diseases; R03 = drugs for obstructive airways diseases; S01 = ophthalmologicals. 
 
